APMs can create problems for vulnerable populations

Patients with disabilities or living in poverty have poorer health outcomes and higher costs. Theoretically, alternative payment models (APMs) could encourage providers to better coordinate care for vulnerable populations and improve their outcomes—but they also have the potential to harm these patients, according to Karen Joynt Maddox, MD, MPH, assistant professor of medicine at Washington University in St. Louis.

Writing in the New England Journal of Medicine, Maddox said clinicians may have incentives in APMs to avoid high-risk patients thanks to risk adjustment which doesn’t separate lower quality care from socioeconomic risk.

“As a result, hospitals or clinics with a high proportion of poor patients may lose money under APMs through no fault of their own,” Maddox wrote. “Particularly in programs with a high level of downside financial risk, there is a powerful incentive for clinicians to avoid providing care for high-risk patients, which could have meaningful consequences for access to care.”

Some APMs, however, have shown evidence of helping this population. In the Medicare Shared Savings Program, for example, organizations which earned shared savings were more likely to serve a higher proportion of disabled or dual-eligible patients.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.